Bio-Gene Advances Flavocide Safety Studies as Qcide Deal Targets Japan’s $1bn Pest Market

FierceBiotechGSK walks away from $100M bet on Mersana's STING ADC, pauses mRNA bird flu shot program

FierceBiotechWhich blockbuster is GSK gunning for next? CEO Miels is looking to oncology

PharmaVoiceRevolution’s on a pancreatic cancer winning streak. What comes next for the biotech?

PharmaVoiceObesity drugmakers chase weight loss. Biohaven is betting on muscles.

Endpoints NewsGSK CEO says team reorg could be in the cards pending upcoming Phase 3 readouts

Endpoints NewsMPM has collected three China drugs for its ‘best of both worlds’ strategy

Endpoints NewsAstraZeneca cuts a couple of late-stage life-cycle trials after disappointing efficacy

10x Genomics NewsA Look At 10x Genomics (TXG) Valuation After The Atera Spatial Biology Platform Launch - simplywall.st

Roche MediaClean-up costs at Roche Pharmaceutical's Clare site pass €150m - MSN

FierceBiotechFDA unveils plan for real-time review of clinical trial data, with AstraZeneca and Amgen already on board

FierceBiotechFDA flags concerns for AstraZeneca's camizestrant, Truqap ahead of advisory committee meeting

10x Genomics NewsVanguard Portfolio Management reports 6.98M TXG shares (NASDAQ: TXG) - Stock Titan